MA41973A - Anticorps anti-igf-1r et son utilisation pour le diagnostic du cancer - Google Patents

Anticorps anti-igf-1r et son utilisation pour le diagnostic du cancer

Info

Publication number
MA41973A
MA41973A MA041973A MA41973A MA41973A MA 41973 A MA41973 A MA 41973A MA 041973 A MA041973 A MA 041973A MA 41973 A MA41973 A MA 41973A MA 41973 A MA41973 A MA 41973A
Authority
MA
Morocco
Prior art keywords
igf
antibodies
cancer diagnosis
diagnosis
cancer
Prior art date
Application number
MA041973A
Other languages
English (en)
Inventor
Alexandra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA41973A publication Critical patent/MA41973A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
MA041973A 2015-04-27 2016-04-27 Anticorps anti-igf-1r et son utilisation pour le diagnostic du cancer MA41973A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15305644 2015-04-27

Publications (1)

Publication Number Publication Date
MA41973A true MA41973A (fr) 2018-03-07

Family

ID=53039834

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041973A MA41973A (fr) 2015-04-27 2016-04-27 Anticorps anti-igf-1r et son utilisation pour le diagnostic du cancer

Country Status (28)

Country Link
US (1) US10457734B2 (fr)
EP (1) EP3288978B1 (fr)
JP (1) JP7086607B2 (fr)
KR (1) KR102350259B1 (fr)
CN (1) CN107709362B (fr)
AR (1) AR105553A1 (fr)
AU (1) AU2016256206B2 (fr)
BR (1) BR112017022635A2 (fr)
CA (1) CA2983071C (fr)
DK (1) DK3288978T3 (fr)
ES (1) ES2797089T3 (fr)
HK (1) HK1248730A1 (fr)
HU (1) HUE049568T2 (fr)
IL (1) IL255272B (fr)
MA (1) MA41973A (fr)
MX (1) MX2017013723A (fr)
MY (1) MY191596A (fr)
NZ (1) NZ736707A (fr)
PL (1) PL3288978T3 (fr)
PT (1) PT3288978T (fr)
RU (1) RU2706959C2 (fr)
SA (1) SA517390221B1 (fr)
SI (1) SI3288978T1 (fr)
TN (1) TN2017000441A1 (fr)
TW (1) TWI716400B (fr)
UA (1) UA122791C2 (fr)
WO (1) WO2016174051A1 (fr)
ZA (1) ZA201707247B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6968790B2 (ja) * 2015-10-26 2021-11-17 ピエール、ファーブル、メディカマン Ｉｇｆ−１ｒ発現癌の処置のための組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
WO2007000328A1 (fr) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
CN101415728A (zh) * 2006-03-28 2009-04-22 比奥根艾迪克Ma公司 抗-igf-1r抗体及其用途
EA200802061A1 (ru) * 2006-03-28 2009-04-28 Байоджен Айдек Эмэй Инк. Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
FR2906533B1 (fr) * 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CA2694990A1 (fr) * 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. Anticorps specifiques de igf-1r utiles dans la detection et le diagnostic de troubles de proliferation cellulaire
AU2008295506A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-IGF-1R antibodies and uses thereof
WO2009126304A1 (fr) * 2008-04-11 2009-10-15 Biogen Idec Ma Inc. Combinaisons thérapeutiques d’anticorps anti-igf-1r et d’autres composés
CN103319597B (zh) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 一种抗胰岛素样生长因子-1受体抗体及其编码基因和应用
CN103319598B (zh) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 抗胰岛素样生长因子-1受体抗体及其编码基因和应用

Also Published As

Publication number Publication date
HK1248730A1 (zh) 2018-10-19
MY191596A (en) 2022-06-30
RU2017140464A (ru) 2019-05-27
SI3288978T1 (sl) 2020-09-30
AU2016256206A1 (en) 2017-11-16
KR20170138465A (ko) 2017-12-15
JP7086607B2 (ja) 2022-06-20
DK3288978T3 (da) 2020-06-02
WO2016174051A1 (fr) 2016-11-03
TWI716400B (zh) 2021-01-21
CA2983071C (fr) 2021-12-14
TN2017000441A1 (en) 2019-04-12
RU2706959C2 (ru) 2019-11-21
EP3288978B1 (fr) 2020-04-08
RU2017140464A3 (fr) 2019-05-30
JP2018516876A (ja) 2018-06-28
MX2017013723A (es) 2018-03-02
TW201643192A (zh) 2016-12-16
NZ736707A (en) 2022-05-27
US20180094060A1 (en) 2018-04-05
IL255272A0 (en) 2017-12-31
PT3288978T (pt) 2020-07-10
AR105553A1 (es) 2017-10-18
ES2797089T3 (es) 2020-12-01
PL3288978T3 (pl) 2020-09-21
UA122791C2 (uk) 2021-01-06
IL255272B (en) 2020-04-30
BR112017022635A2 (pt) 2018-07-17
CN107709362A (zh) 2018-02-16
CA2983071A1 (fr) 2016-11-03
US10457734B2 (en) 2019-10-29
KR102350259B1 (ko) 2022-01-11
CN107709362B (zh) 2021-08-13
AU2016256206B2 (en) 2020-04-30
ZA201707247B (en) 2023-07-26
SA517390221B1 (ar) 2022-02-22
HUE049568T2 (hu) 2020-09-28
EP3288978A1 (fr) 2018-03-07

Similar Documents

Publication Publication Date Title
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
ZA201700832B (en) Anti-pd-l1 antibodies and diagnostic uses thereof
KR20180084980A (ko) 진단 장치, 컴퓨터 프로그램, 및 진단 시스템
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA42238A (fr) Procédés de diagnostic du cancer de la vessie
ES2968016T3 (es) Dispositivo de evaluación médica
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA47811A (fr) Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer
IL265485A (en) Diagnostic anti-PD-L1 antibody and its use
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
GB201413357D0 (en) Antibodies for treatment and diagnosis
BR112017015217A2 (pt) chip diagnóstico
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
HK1243434A1 (zh) Igf-1r抗體及其診斷癌症的用途
FR3033747B1 (fr) Dispositif de diagnostic
MA41973A (fr) Anticorps anti-igf-1r et son utilisation pour le diagnostic du cancer
PL2984108T3 (pl) Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu
FR3057070B1 (fr) Diagnostique et pronostique precoce de la preeclampsie
DE112016004129A5 (de) Elektrolinearmotor und Prüfeinrichtung
DK3222994T3 (da) Undersøgelsesanordning med forstørrelsesfunktion
GB201500875D0 (en) Antibodies for treatment and diagnosis
MA51152A (fr) Anticorps de bêta-globine falciformes
UA29844S (uk) Апарат рентгено діагностичний пересувний